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Abstract 
Epithelioid cell tumors presenting in the gastrointestinal tract are uncommon, but when 
they arise, arriving at a correct diagnosis is important. We report a case of anal malignant 
melanoma in an 82-year-old man who microscopically showed an epithelioid malignant 
tumor simulating a gastrointestinal stromal tumor. C-kit stain and Melan-A were diffusely 
and strongly positive, while HMB-45 was focally positive. This case illustrates the 
potential pitfall of relying on a single antibody or inadequate panel of 
immunohistochemical stains to confirm the diagnosis. We recommend to apply an 
adequate immunohistochemical panel which includes S-100 protein, HMB-45 and 
Melan-A in order to make an accurate diagnosis, and discuss the differential diagnosis 
and surgical treatment modalities. 
 
Introduction 
Anorectal melanomas (ARM) are uncommon neoplasias, and most of them are 
metastases from a cutaneous primary [1]. Primary ARM represents 0.4 to 1.6% of all 
melanoma manifestations [2, 3]. Nevertheless, the anorectum is the most common site of 
primary melanoma in the alimentary tract [4]. 
Malignant melanoma (MM) occurs in up to 15% of primary malignant tumors of the 
anus. The tumor originates from melanocytes that are normally found in the transitional 
zone above the dentate line. In early stages, it can mimic clinically thrombosed  
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hemorrhoids [5]. Grossly ARM may display a polypoid mass covered by a smooth surface 
which may eventually be ulcerated and usually extends into the lower rectum. The 
epidemiology of ARM has not been studied, although its putative relevance and 
prognostic studies have been based on referred cases [6]. Some epidemiologic data 
suggest that immunodeficiency virus infection increases the risk of ARM [3, 7]. Due to its 
low incidence, treatment of ARM is not well standardized since it was implemented based 
on retrospective studies referring to a short series of cases from data collected for up to 64 
years [7]. 
The most frequent presentation is rectal bleeding, followed by palpable mass and pain 
[8]. ARM presents as a large protuberant or ulcerating mass which usually extends into 
the lower rectum. The mass is pigmented in only one third of cases. Most patients present 
with lesions >2 mm thick. At the time of diagnosis about 30% of cases present distant 
metastases, and metastases eventually develop in 60% [6, 7, 9, 10]. 
Case Report 
An 82-year-old man complained of rectal bleeding. Physical examination showed a polypoid and 
firm tumor mass which was thought to be clinically malignant. No endoscopic study was performed. 
Chest X-ray and whole-body computed tomography failed to show any tumor mass. The patient 
underwent a local transrectal resection of the anorectal mass. 
Pathologic Findings 
The gross specimen was a segmental anorectal resection measuring 2.6 × 1.7 × 0.7 cm. In the center, 
a polypoid well-delimitated lesion, measuring 1.7 cm in diameter, which was whitish and elastic, was 
observed. Microscopically, the tumor was located in the submucosa and muscularis mucosae and 
extended to rectal mucosa infiltrating lamina propria. Extensive areas of ulceration were present. No 
junctional activity or connection was observed with the lining squamous upper mucosa. The tumor cells 
were epithelioid with abundant cytoplasms and paranuclear clear spaces. The nuclei were round and 
showed prominent nucleoli. Mitotic figures were frequent and atypical, averaged 16 per 10 high-power 
fields. Vascular or perineural invasion was not observed. The surgical margins were free of tumor. The 
tumor cells showed strong positivity for vimentin (V9), CD117 (C-kit), S-100 protein, and MART-1 
(Melan-A). HMB-45 stain was focally positive at the inner portion of the tumor (20% of the cells). Stains 
for cytokeratins, smooth muscle actin, desmin, h-caldesmon, chromogranin, synaptophysin and CD34 
(QBEN-10) were negative. With ki67 the proliferative activity was 60%. A diagnosis of submucosal 
amelanotic malignant melanoma, ulcerated of the anus, Breslow 2.8 mm thick, was made. After the 
diagnosis, the patient was examined by a dermatologist and no skin lesion suggestive of cutaneous 
melanoma was observed. The patient denied any complementary surgical treatment. Currently, 5 
months after the diagnosis, the patient is well and free of tumor. 
Discussion 
Anal melanomas exhibit the same immunohistochemical and ultrastructural features 
as their cutaneous counterparts [11]. However, similar to melanomas arising in other 
mucous membranes, they are typical of the acrolentiginous type. Invasive melanomas in 
this region are commonly epithelioid, although spindle cell and desmoplastic variants 
have been described. 
Differentiation of anal malignant amelanotic epithelioid melanoma from Paget’s 
disease, lymphoma, undifferentiated carcinoma and gastrointestinal stromal tumor 
(GIST) can be difficult on the basis of histologic criteria alone. Immunostains are of 
invaluable help to make the diagnosis accurately. In Paget’s disease, the tumor cells 
should stain with cytokeratins. Lymphoma should stain for CD45 and CDs.  
Case Rep Oncol 2009;2:30–37 
DOI: 10.1159/000204788 
Published online: February 28, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
32
Undifferentiated carcinoma may stain with chromogranin and synaptophysin. The most 
challenging diagnosis in this particular case were GIST and epithelioid leiomyosarcomas. 
The microscopic appearance should indicate a malignant epithelioid GIST, with high risk 
of metastasis because of the presence of nuclear atypia and large number of mitosis/HPF. 
Although it is infrequent to find a high-grade GIST measuring less than 2 cm, it could be 
possible. Rectal GISTs are nearly always positive for CD34 [12]. Unlike leiomyomas and 
leiomyosarcomas, colorectal GISTs rarely present as mucosal polyps because they arise 
within the muscularis propria [12, 13]. Besides, those muscular tumors stain positively 
with smooth muscle antigens (desmin and caldesmon), all of which were negative in our 
case. It should be kept in mind that c-kit positivity is not specific of GIST. In fact it is 
well-known that leukemias, some lymphomas, germinal cell tumors, and melanomas 
show positive results with this antibody, and awareness of this is important in order to 
prevent a diagnostic error with treatment and outcome consequences [14–16]. Further, its 
application should be interpreted in an appropriate context. Chute el al. studied a series of 
17 cases of ARM and reported that c-kit is frequently expressed (75%), although specific 
melanoma markers HMB-45 and Melan-A are not always expressed in this tumor [17]. 
On the other hand, melanomas may not always uniformly stain for HMB-45. It should be 
realized that MART-1 (Melan-A) may be positive in cases of melanomas which 
completely lack reactivity or show a heterogeneous pattern of reactivity with HMB-45 
stain, as in the case discussed here. Recently, Seya et al. [18] reported a rectal malignant 
melanoma that was misdiagnosed in the endoscopic biopsy as neuroendocrine carcinoma 
or GIST because of the reactivity with CD56, S100 and CD117, and a malignant 
melanoma was ruled out because HMB-45 was negative. However, the study of the 
surgical specimen showed HMB-45 and Mart-1 reactivity in both biopsy and surgical 
specimen [18]. The phenotypic variability is most likely due to tumor heterogeneity or 
suboptimal fixation. Similarly, if our case had been endoscopically biopsied and if a 
limited immunohistochemical panel of antibodies would have been employed, such as 
cytokeratins–, CD34–/+, Ckit+ and HMB-45– (in the main part of the tumor mass, nearly 
80%), a misdiagnosis of GIST would have been more likely. Therefore, we favor the 
application of an adequate immunohistochemical panel in epithelioid tumors of the 
anorectal region in order to rule out leiomyosarcoma, GIST or MM, which pursue 
different biological behaviors. In the case of suspected malignant melanoma, this panel 
should include S-100, vimentin and both specific antibodies HMB-45 and Mart-1. Once a 
diagnosis of malignant melanoma has been established, it must be determined whether 
the tumor is primary or metastatic. The presence of junctional activity beneath the 
squamous epithelium favors a primary malignant melanoma, although it may be 
obscured by ulceration. In fact, our case showed large areas of ulceration which could 
miss this important key feature. However, the absence of the obviously helpful history of 
primary melanoma elsewhere should it exist; we assumed confidently that the tumor was 
primarily from the anorectal region. 
The prognosis of anal melanoma is poor, regardless of the type of treatment [7, 10, 19], 
with a mean 5-year survival of approximately 15% [3, 20], ranging from 6 to 31% [21, 22]. 
Thus, ARM may represent a systemic disease at the time of diagnosis in most cases, and 
the choice of surgical or other local procedures to amend the primary tumor may not 
have great influence on the systemic course of the disease. Most recurrences occur within 
the first 30 months, and common sites are the inguinal lymph nodes, lung, liver and 
bones. Local recurrence is almost always associated with or followed by regional or 
disseminated disease. The thickness of the tumor measured from the top of the overlying 
intact mucosa or ulcerated tumor correlates with the outcome. Anal melanomas of less 
than 2.0 mm in thickness have better prognosis than those greater than 2.0 mm in 
thickness.  
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Regarding the surgical treatment of ARM, it is a matter of debate between wide local 
excision (WLE) and abdominoperineal resection (APR). A meta-analysis which included 
compiled data of 426 patients failed to show the advantage of either approach with respect 
to the overall survival [19]. It should be noted, however, that in most studies it was 
difficult to compare patients’ prognostic factors due to the fact that the information 
provided was insufficient. Nevertheless, there was a trend for local disease to be more 
effectively controlled by APR than WLE [4, 10, 19, 23]. Ballo et al. [22] reported that 
adjuvant radiation of the pelvis and inguinal lymph nodes after WLE showed similar rates 
of local tumor control as APR. WLE should be the procedure of choice for other 
investigators, because the alternative of APR may have a high mortality rate and lack of 
survival advantages [24]. 
In ARM treatment, therapeutic strategies should be adjusted to the prognosis of the 
disease. Prognostic parameters still remain to be defined. Only a few studies have 
addressed this question. Goldman et al. [9] reported a correlation between overall survival 
and the size of the tumor. Among 33 patients, only 2 were long-term survivors and the 
tumor was less than 2 cm in diameter. The tumor thickness was below 2.5 mm. 
Unfortunately, the histopathologic data were not provided for all patients. On the other 
hand, Slingluff et al. [21] suggested that the only significant value for survival was the 
stage of disease at the time of diagnosis, whereas Ballo et al. reported a favorable disease-
free survival with less than 4 mm of tumor thickness [22]. More recently, a series of 19 
patients with ARM were studied [25]. The median tumor thickness was 10 mm (range 
0.6–40 mm). 9 out of 19 patients presented either regional or distant metastases at the 
time of diagnosis. The remaining 13 patients were treated with curative intent (APR or 
WLE). There were no significant differences in overall survival. The incidence of local 
recurrences was lower following APR even for patients with less favorable tumors. The 
authors concluded that WLE alone is not sufficient for local tumor control in thick ARM. 
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Fig. 1. a Anal malignant melanoma lined by epithelial mucinous cells. HE. ×400. b Rectal malignant 
melanoma lined by squamous rectal epithelium. Note the large ulcerated areas (arrows). HE. ×400. 
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Fig. 2. a Tumor cells showed strong and diffuse reactivity with C-kit. CD117 stain ×400. b Only 20% of 
tumor cells showed positivity with HMB-45, in the deeper portion (arrows). HMB-45 stain ×100. c The 
tumor showed diffuse and strong positivity with Melan-A. Note the absence of junctional features. 
Mart-1 ×100. d Epithelioid atypical cells infiltrating rectal glands. Mart-1 ×400. 
 
  
Case Rep Oncol 2009;2:30–37 
DOI: 10.1159/000204788 
Published online: February 28, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
36
References 
1  McDermott VG, Low VH, Keogan MT, et al: Malignant melanoma metastatic to 
the gastrointestinal tract. AJR Am J Roentgenol 1996;166:809–813. 
2  Wanebo HJ, Woodruff JM, Farr GH, Quan SH: Anorectal melanoma. Cancer 
1981;47:1891–1900. 
3  Cagir B, Whiteford MH, Topham A, et al: Changing epidemiology of anorectal 
melanoma. Dis Colon Rectum 1999;42:1203–1208. 
4  Roumen RM: Anorectal melanoma in The Netherlands: a report of 63 patients. 
Eur J Surg Oncol 1996;22:598–601. 
5  Felz MW, Winburn GB, Kallab AM, Lee JR: Anal melanoma: an aggressive 
malignancy masquerading as hemorrhoids. South Med J 2001;94:880–885. 
6  Weinstock MA: Epidemiology and prognosis of anorectal melanoma. 
Gastroenterology 1993;104:174–178. 
7  Brady MS, Kavolius JP, Quan SH: Anorectal melanoma. A 64-year experience at 
Memorial Sloan-Kettering Cancer Center. Dis Colon Rectum 1995;38:146–151. 
8  Angeras U, Jönsson N, Jönsson PE: Primary anorectal malignant melanoma. J 
Surg Oncol 1983;22:261–264. 
9  Goldman S, Glimelius B, Pahlman L: Anorectal malignant melanoma in Sweden. 
Report of 49 patients. Dis Colon Rectum 1990;33:874–877. 
10  Ross M, Pezzi C, Pezzi T, et al: Patterns of failure in anorectal melanoma. A guide 
to surgical therapy. Arch Surg 1990;125:313–316. 
11  Ben-Izhak O, Levy R, Weill S, et al: Anorectal malignant melanoma. A 
clinicopathologic study, including immunohistochemistry and DNA flow 
cytometry. Cancer 1997;79:18–25. 
12  Miettinen M, Sarlomo-Rikala M, Sobin LH: Mesenchymal tumors of muscularis 
mucosae of colon and rectum are benign leiomyomas that should be separated 
from gastrointestinal stromal tumors – a clinicopathologic and 
immunohistochemical study of eighty-eight cases. Mod Pathol 2001;14:950–956. 
13  Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J: Gastrointestinal stromal 
tumors and leiomyosarcomas in the colon: a clinicopathologic, 
immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 
2000;24:1339–1352. 
14  Furitsu T, Tsujimura T, Tono T, et al: Identification of mutations in the coding 
sequence of the proto-oncogene c-Kit in a human mast cell leukemia cell line 
causing ligand-independent activation of c-Kit product. J Clin Invest 
1993;92:1736–1744. 
15  Longley BJ, Tyrrell L, Lu SZ, et al: Somatic c-KIT activating mutation in urticaria 
pigmentosa and aggressive mastocytosis: establishment of clonality in human 
mast cell neoplasm. Nat Genet 1996;12:312–314. 
16  Palumbo C, van Roozendaal K, Gillis AJ, van Gurp RH, de Munnik H, Oosterhuis 
JW, van Zoelen EJ, Looijenga LH: Expression of the PDGF alpha-receptor 1.5 kb 
transcript, OCT-4, and c-KIT in human normal and malignant tissues. 
Implications for the early diagnosis of testicular germ tumours and for our 
understanding of regulatory mechanisms. J Pathol 2002;196:467–477. 
17  Chute DJ, Cousar JB, Mills SE: Anorectal malignant melanoma: morphologic and 
immunohistochemical features. Am J Clin Pathol 2006;126:93–100. 
18  Seya T, Tanaka N, Shinji S, Shinji E, Yokoi K, Horiba K, Kanazawa Y, Yamada T, 
Oaki Y, Tajiri T: Case of rectal malignant melanoma showing 
immunohistochemical variability in a tumor. J Nippon Med Sch 2007;74:377–381. 
19  Thibault C, Sagar P, Nivatvongs S, et al: Anorectal melanoma – an incurable 
disease? Dis Colon Rectum 1997;40:661–668. 
20  Rossetti C, Koukouras D, Eboli M, et al: Primary anorectal melanomas: an 
institutional experience. J Exp Clin Cancer Res 1997;16:81–85. 
21  Slingluff CL Jr, Vollmer RT, Seigler HF: Anorectal melanoma: clinical 
characteristics and results of surgical management in twenty-four patients. 
Surgery 1990;107:1–9. 
22  Ballo MT, Gershenwald JE, Zagars GK, et al: Sphincter-sparing local excision and 
adjuvant radiation for anal-rectal melanoma. J Clin Oncol 2002;20:4555–4558.  
Case Rep Oncol 2009;2:30–37 
DOI: 10.1159/000204788 
Published online: February 28, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
37
23  Abbas JS, Karakousis CP, Holyoke ED: Anorectal melanoma: clinical features, 
recurrence and patient survival. Int Surg 1980;65:423–426. 
24  Droesch JT, Flum DR, Mann GN: Wide local excision or abdominoperineal 
resection as the initial treatment for anorectal melanoma? Am J Surg 
2005;189:446–449. 
25  Weyandt GH, Eggert AO, Houf M, Raulf F, Bröcker EB, Becker JC: Anorectal 
melanoma: surgical management guidelines according to tumour thickness. Br J 
Cancer 2003;89:2019–2022. 
 